Biaryl substituted alkylboronate esters as thrombin inhibitors
摘要:
Thrombin is a serine protease that plays an important role in the blood coagulation cascade, and is a target enzyme for new therapeutic agents. Ac-(D)-Phe-Pro-boroArg-OH (DuP714) was found to be a highly effective thrombin inhibitor. In order to reduce the peptidic nature of DuP 714, we have designed a series of novel biaryl substituted alkylboronate esters as potent thrombin inhibitors. The most potent compounds have subnanomolar affinity for thrombin. (C) 1997 The DuPont Merck Pharmaceutical Company. Published by Elsevier Science Ltd.
New P2X3 receptor antagonists. Part 2: Identification and SAR of quinazolinones
作者:Gábor Szántó、Attila Makó、István Vágó、Tamás Hergert、Imre Bata、Bence Farkas、Sándor Kolok、Mónika Vastag
DOI:10.1016/j.bmcl.2016.07.013
日期:2016.8
Numerous potent P2X3 antagonists have been discovered and the therapeutic potential of P2X3 antagonism already comprises proof-of-concept data obtained in clinical trials with the most advanced compound. We have lately reported the discovery and optimization of thia-triaza-tricycle compounds with potent P2X3 antagonistic properties. This Letter describes the SAR of a back-up series containing a 4-oxo-quinazoline
Inhibitory Kappa B Kinase α (IKKα) Inhibitors That Recapitulate Their Selectivity in Cells against Isoform-Related Biomarkers
作者:Nahoum G. Anthony、Jessica Baiget、Giacomo Berretta、Marie Boyd、David Breen、Joanne Edwards、Carly Gamble、Alexander I. Gray、Alan L. Harvey、Sophia Hatziieremia、Ka Ho Ho、Judith K. Huggan、Stuart Lang、Sabin Llona-Minguez、Jia Lin Luo、Kathryn McIntosh、Andrew Paul、Robin J. Plevin、Murray N. Robertson、Rebecca Scott、Colin J. Suckling、Oliver B. Sutcliffe、Louise C. Young、Simon P. Mackay
DOI:10.1021/acs.jmedchem.7b00484
日期:2017.8.24
IKK beta plays a central role in the canonical NF-kB pathway, which has been extensively characterized. The role of IKK alpha in the noncanonical NF-kB pathway, and indeed in the canonical pathway as a complex with IKK beta, is less well understood. One major reason for this is the absence of chemical tools designed as selective inhibitors for IKK alpha over IKK beta. Herein, we report for the first time a series of novel, potent, and selective inhibitors of IKK alpha. We demonstrate effective target engagement and selectivity with IKK alpha in U2OS cells through inhibition of IKK alpha-driven p100 phosphorylation in the noncanonical NF-kB pathway without affecting IKK beta-dependent IKapp-B alpha loss in the canonical pathway. These compounds represent the first chemical tools that can be used to further characterize the role of IKK alpha a in cellular signaling, to dissect this from IKK beta and to validate it in its own right as a target in inflammatory diseases.